Portage Biotech Inc. (PRTG) - Long-Term Liabilities to Capital

This daily price chart of the asset's market trend on the GURU.Markets platform reflects indicators at 0.00, while Portage Biotech Inc. (PRTG) develops anti-tumor methods through partnerships with specialized centers. However, a funding shortage has led to a freeze in trials and a loss of cash flow. Despite the crisis, the scientific community values the company for its pursuit of ways to combat resistant forms of cancer.

Portage Biotech Inc. (PRTG) focuses on oncology R&D, planning monetization through the licensing of formulas. This metric compares long-term liabilities to total equity, determining the financial stability of the balance sheet structure. Analyzing the long-term debt-to-net assets ratio on GURU.Markets allows for tracking the level of leverage. A low debt load is critical for biotech companies prior to the completion of trials. This confirms the asset's conservative risk profile.